PFGKX
Price
$35.23
Change
-$0.11 (-0.31%)
Updated
Jun 2 closing price
Net Assets
6.52B
RGAGX
Price
$88.82
Change
-$0.29 (-0.33%)
Updated
Jun 2 closing price
Net Assets
337.53B
Interact to see
Advertisement

PFGKX vs RGAGX

Header iconPFGKX vs RGAGX Comparison
Open Charts PFGKX vs RGAGXBanner chart's image
PFGKX vs RGAGX Comparison Chart in %
View a ticker or compare two or three
VS
PFGKX vs. RGAGX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PFGKX is a StrongBuy and RGAGX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGAGX has more cash in the bank: 338B vs. PFGKX (6.52B). RGAGX pays higher dividends than PFGKX: RGAGX (0.51) vs PFGKX (0.00). PFGKX was incepted earlier than RGAGX: PFGKX (13 years) vs RGAGX (17 years). PFGKX (0.67) is less costly to investors than RGAGX (0.29). RGAGX is a more actively managed with annual turnover of: 32.00 vs. PFGKX (26.00). PFGKX has a lower initial minimum investment than RGAGX: PFGKX (0) vs RGAGX (250). RGAGX annual gain was more profitable for investors over the last year : 15.41 vs. PFGKX (-1.26). RGAGX return over 5 years is better than : 27.14 vs. PFGKX (5.71).
PFGKXRGAGXPFGKX / RGAGX
Total Expense Ratio0.650.29224%
Annual Report Gross Expense Ratio0.670.29231%
Fund Existence13 years17 years-
Gain YTD5.05410.59948%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets6.52B338B2%
Annual Yield % from dividends0.000.51-
Returns for 1 year-1.2615.41-8%
Returns for 3 years26.4755.3148%
Returns for 5 years5.7127.1421%
Returns for 10 years91.92117.0679%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RIO111.672.71
+2.49%
Rio Tinto plc
BAYA12.300.10
+0.82%
Bayview Acquisition Corp
PSN60.840.18
+0.30%
Parsons Corp
IDT55.41-0.56
-1.00%
IDT Corp
LCTX1.21-0.05
-3.97%
Lineage Cell Therapeutics